Genprex (GNPX) Competitors $0.19 -0.02 (-7.41%) As of 11:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. VRCA, LVTX, GRCE, OKUR, DYAI, KLTO, JSPR, ATHE, XFOR, and ELUTShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Verrica Pharmaceuticals (VRCA), LAVA Therapeutics (LVTX), Grace Therapeutics (GRCE), OnKure Therapeutics (OKUR), Dyadic International (DYAI), Klotho Neurosciences (KLTO), Jasper Therapeutics (JSPR), Alterity Therapeutics (ATHE), X4 Pharmaceuticals (XFOR), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Its Competitors Verrica Pharmaceuticals LAVA Therapeutics Grace Therapeutics OnKure Therapeutics Dyadic International Klotho Neurosciences Jasper Therapeutics Alterity Therapeutics X4 Pharmaceuticals Elutia Verrica Pharmaceuticals (NASDAQ:VRCA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Which has stronger valuation and earnings, VRCA or GNPX? Genprex has lower revenue, but higher earnings than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$14.70M2.58-$76.58M-$8.28-0.48GenprexN/AN/A-$21.11MN/AN/A Which has more risk & volatility, VRCA or GNPX? Verrica Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.71, indicating that its stock price is 171% less volatile than the S&P 500. Do analysts rate VRCA or GNPX? Verrica Pharmaceuticals presently has a consensus target price of $60.00, indicating a potential upside of 1,395.14%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Genprex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media refer more to VRCA or GNPX? In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 3 mentions for Genprex. Genprex's average media sentiment score of 0.63 beat Verrica Pharmaceuticals' score of 0.47 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in VRCA or GNPX? 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is VRCA or GNPX more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets Verrica PharmaceuticalsN/A N/A -115.48% Genprex N/A -809.27%-386.95% SummaryVerrica Pharmaceuticals beats Genprex on 10 of the 12 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.71M$3.34B$6.06B$10.38BDividend YieldN/A2.31%5.73%4.78%P/E RatioN/A22.1986.0626.86Price / SalesN/A415.96582.90180.66Price / CashN/A44.9825.7330.17Price / Book1.2710.3012.686.63Net Income-$21.11M-$52.31M$3.31B$276.12M7 Day Performance-7.00%0.15%-0.66%-1.86%1 Month Performance-34.86%13.31%8.45%5.63%1 Year Performance-43.92%27.02%77.27%32.94% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex1.1682 of 5 stars$0.19-7.4%N/A-39.4%$8.71MN/A0.0020VRCAVerrica Pharmaceuticals3.9853 of 5 stars$4.30-2.7%$60.00+1,295.3%-69.1%$41.75M$7.57M-0.5240LVTXLAVA Therapeutics1.8286 of 5 stars$1.56-1.3%$2.69+72.1%-6.1%$41.56M$11.98M-1.4960GRCEGrace Therapeutics2.7258 of 5 stars$3.02+0.7%$12.00+297.4%N/A$41.53MN/A-3.51N/ANegative NewsHigh Trading VolumeOKUROnKure Therapeutics3.8049 of 5 stars$3.13+3.0%$32.33+933.0%-83.4%$41.13MN/A-0.65N/ANews CoverageDYAIDyadic International3 of 5 stars$1.13flat$6.00+431.0%-6.3%$40.89M$3.49M-5.957KLTOKlotho Neurosciences1.0545 of 5 stars$0.62+6.7%N/A+12.7%$40.81MN/A-1.38N/AGap UpJSPRJasper Therapeutics3.3617 of 5 stars$2.49+3.8%$25.63+929.1%-84.0%$39.01MN/A-0.4120ATHEAlterity Therapeutics2.6044 of 5 stars$4.50+4.4%$12.00+166.7%+233.9%$38.22MN/A0.0010High Trading VolumeXFORX4 Pharmaceuticals4.2101 of 5 stars$3.43+3.3%$34.17+896.1%-79.9%$37.88M$32.77M-0.2380ELUTElutia3.1188 of 5 stars$0.88-0.7%$7.00+693.2%-75.9%$37.69M$23.68M-0.83180 Related Companies and Tools Related Companies VRCA Competitors LVTX Competitors GRCE Competitors OKUR Competitors DYAI Competitors KLTO Competitors JSPR Competitors ATHE Competitors XFOR Competitors ELUT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
